{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:09:09Z","timestamp":1780664949264,"version":"3.54.1"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82200989"],"award-info":[{"award-number":["82200989"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"crossref","award":["ZR2024MH065"],"award-info":[{"award-number":["ZR2024MH065"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Key Research and Development Program of China","award":["2024YFC2510500"],"award-info":[{"award-number":["2024YFC2510500"]}]},{"name":"key Program of Innovation Improvement of Small and Medium-sized Enterprises of Shandong Province in China","award":["2023TSGC0717"],"award-info":[{"award-number":["2023TSGC0717"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Rev and Rep"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12015-026-11136-2","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:19:35Z","timestamp":1777274375000},"page":"2252-2265","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Thrombopoietin Receptor MPL in Hematopoiesis and Myeloproliferative Neoplasms: Physiological Roles and Pathogenic Mechanisms"],"prefix":"10.1007","volume":"22","author":[{"given":"Shujing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Sameer","family":"Ashaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiqi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baobing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"issue":"4","key":"11136_CR1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/10428194.2017.1357179","volume":"59","author":"S Thota","year":"2018","unstructured":"Thota, S., & Gerds, A. T. (2018). Myelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes. Leukemia & Lymphoma, 59(4), 803\u2013812.","journal-title":"Leukemia & Lymphoma"},{"key":"11136_CR2","doi-asserted-by":"crossref","unstructured":"Nann, D., & Fend, F. (2021). Synoptic Diagnostics of Myeloproliferative Neoplasms: Morphology and Molecular Genetics. Cancers, 13(14).","DOI":"10.3390\/cancers13143528"},{"issue":"5","key":"11136_CR3","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1055\/a-0781-8602","volume":"144","author":"B Gappa","year":"2019","unstructured":"Gappa, B., Griesshammer, M., & Sadjadian, P. (2019). Classification and Personalized Prognosis in Myeloproliferative Neoplasms. Deutsche Medizinische Wochenschrift, 144(5), 298\u2013.","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"4","key":"11136_CR4","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/PAP.0000000000000493","volume":"32","author":"S Prakash","year":"2025","unstructured":"Prakash, S., & Orazi, A. (2025). Diagnostic Approach to Myeloproliferative Neoplasms and Myelodysplastic\/Myeloproliferative Neoplasms. Advances in Anatomic Pathology, 32(4), 284\u2013298.","journal-title":"Advances in Anatomic Pathology"},{"issue":"1","key":"11136_CR5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1515\/medgen-2024-2003","volume":"36","author":"C Kuehn","year":"2024","unstructured":"Kuehn, C., Hoerst, K., Kvasnicka, H. M., et al. (2024). Genetic alterations in myeloproliferative and myelodysplastic\/myeloproliferative neoplasms - a practical guide to WHO-HAEM5. Medizinische Genetik, 36(1), 31\u201338.","journal-title":"Medizinische Genetik"},{"issue":"3","key":"11136_CR6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1053\/j.semdp.2023.04.005","volume":"40","author":"PP Patwardhan","year":"2023","unstructured":"Patwardhan, P. P., Aarabi, M., & Aggarwal, N. (2023). Genomics of myelodysplastic\/myeloproliferative neoplasm. Seminars in Diagnostic Pathology, 40(3), 195\u2013201.","journal-title":"Seminars in Diagnostic Pathology"},{"issue":"12","key":"11136_CR7","doi-asserted-by":"crossref","first-page":"5186","DOI":"10.1182\/blood-2006-08-044503","volume":"109","author":"JL Abkowitz","year":"2007","unstructured":"Abkowitz, J. L., & Chen, J. (2007). Studies of c-Mpl function distinguish the replication of hematopoietic stem cells from the expansion of differentiating clones. Blood, 109(12), 5186\u20135190.","journal-title":"Blood"},{"issue":"11","key":"11136_CR8","doi-asserted-by":"crossref","first-page":"394A","DOI":"10.1182\/blood.V108.11.1350.1350","volume":"108","author":"JL Abkowitz","year":"2006","unstructured":"Abkowitz, J. L., & Chen, J. (2006). Studies of c-Mpl function distinguish the survival and proliferation of hematopoietic stem cells (HSC) from the expansion of differentiating clones. Blood, 108(11), 394A\u2013394A.","journal-title":"Blood"},{"issue":"2","key":"11136_CR9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.hoc.2020.12.002","volume":"35","author":"J Szybinski","year":"2021","unstructured":"Szybinski, J., & Meyer, S. C. (2021). Genetics of Myeloproliferative Neoplasms. Hematology-Oncology Clinics of North America, 35(2), 217\u2013236.","journal-title":"Hematology-Oncology Clinics of North America"},{"issue":"22","key":"11136_CR10","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1182\/blood-2018-01-791491","volume":"131","author":"F Passamonti","year":"2018","unstructured":"Passamonti, F., & Maffioli, M. (2018). The role of JAK2 inhibitors in MPNs 7 years after approval. Blood, 131(22), 2426\u20132435.","journal-title":"Blood"},{"issue":"26","key":"11136_CR11","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2014-07-587238","volume":"124","author":"V Sangkhae","year":"2014","unstructured":"Sangkhae, V., Etheridge, S. L., Kaushansky, K., et al. (2014). The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm. Blood, 124(26), 3956\u20133963.","journal-title":"Blood"},{"issue":"7","key":"11136_CR12","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1182\/blood.V87.7.2641.bloodjournal8772641","volume":"87","author":"RJ Dandrea","year":"1996","unstructured":"Dandrea, R. J., Barry, S. C., Moretti, P. A. B., et al. (1996). Extracellular truncations of h\u03b2c, the common signaling subunit for interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF), and IL-5, lead to ligand-independent activation. Blood, 87(7), 2641\u20132648.","journal-title":"Blood"},{"key":"11136_CR13","doi-asserted-by":"crossref","unstructured":"Bratkowski, M., Mafi, A., Geng, J. (2023). Structural Basis for Activation of the Thrombopoietin Receptor (MPL) By Its Ligand (TPO). Blood, 142.","DOI":"10.1182\/blood-2023-182088"},{"issue":"3","key":"11136_CR14","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.bmc.2016.12.022","volume":"25","author":"Y Liu","year":"2017","unstructured":"Liu, Y., Tian, F., Zhi, D., et al. (2017). Novel thrombopoietin mimetic peptides bind c-Mpl receptor: Synthesis, biological evaluation and molecular modeling. Bioorganic & Medicinal Chemistry, 25(3), 1113\u20131121.","journal-title":"Bioorganic & Medicinal Chemistry"},{"issue":"19","key":"11136_CR15","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1016\/j.cell.2023.07.037","volume":"186","author":"N Tsutsumi","year":"2023","unstructured":"Tsutsumi, N., Masoumi, Z., James, S. C., et al. (2023). Structure of the thrombopoietin-MPL receptor complex is a blueprint for hematopoiesis. Cell, 186(19), 4189\u2013.","journal-title":"Cell"},{"issue":"50","key":"11136_CR16","doi-asserted-by":"crossref","first-page":"38930","DOI":"10.1074\/jbc.M607524200","volume":"281","author":"W Tong","year":"2006","unstructured":"Tong, W., Sulahian, R., Gross, A. W., et al. (2006). The membrane-proximal region of the thrombopoietin receptor confers its high surface expression by JAK2-dependent and -independent mechanisms. Journal of Biological Chemistry, 281(50), 38930\u201338940.","journal-title":"Journal of Biological Chemistry"},{"issue":"6","key":"11136_CR17","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1182\/blood-2008-01-134049","volume":"112","author":"IS Hitchcock","year":"2008","unstructured":"Hitchcock, I. S., Chen, M. M., King, J. R., et al. (2008). YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor regulate receptor internalization and degradation. Blood, 112(6), 2222\u20132231.","journal-title":"Blood"},{"key":"11136_CR18","doi-asserted-by":"crossref","unstructured":"Han, L. J., Schubert, C., K\u00f6hler, J. (2016). Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion. Journal of Hematology & Oncology, 9.","DOI":"10.1186\/s13045-016-0275-0"},{"issue":"9","key":"11136_CR19","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/tra.12185","volume":"15","author":"C Cleyrat","year":"2014","unstructured":"Cleyrat, C., Darehshouri, A., Steinkamp, M. P., et al. (2014). Mpl Traffics to the Cell Surface Through Conventional and Unconventional Routes. Traffic (Copenhagen, Denmark), 15(9), 961\u2013982.","journal-title":"Traffic (Copenhagen, Denmark)"},{"issue":"6","key":"11136_CR20","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/s41375-024-02219-5","volume":"38","author":"K Behrens","year":"2024","unstructured":"Behrens, K., Kauppi, M., Viney, E. M., et al. (2024). Differential in vivo roles of Mpl cytoplasmic tyrosine residues in murine hematopoiesis and myeloproliferative disease. Leukemia, 38(6), 1342\u20131352.","journal-title":"Leukemia"},{"issue":"16","key":"11136_CR21","first-page":"5884","volume":"111","author":"AP Ng","year":"2014","unstructured":"Ng, A. P., Kauppi, M., Metcalf, D., et al. (2014). Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation. Proceedings of the National Academy of Sciences of the United States of America, 111(16), 5884\u20135889.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"11136_CR22","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1182\/blood-2009-11-252569","volume":"115","author":"W Tong","year":"2010","unstructured":"Tong, W. (2010). A means to an end: ubiquitination of Mpl. Blood, 115(6), 1111\u20131112.","journal-title":"Blood"},{"issue":"3","key":"11136_CR23","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00062752-200005000-00010","volume":"7","author":"JG Drachman","year":"2000","unstructured":"Drachman, J. G. (2000). Role of thrombopoietin in hematopoietic stem cell and progenitor regulation. Current Opinion in Hematology, 7(3), 183\u2013190.","journal-title":"Current Opinion in Hematology"},{"issue":"1","key":"11136_CR24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.exphem.2005.09.008","volume":"34","author":"AE Geddis","year":"2006","unstructured":"Geddis, A. E., Fox, N. E., & Kaushansky, K. (2006). The Mpl receptor expressed on endothelial cells does not contribute significantly to the regulation of circulating thrombopoietin levels. Experimental Hematology, 34(1), 82\u201386.","journal-title":"Experimental Hematology"},{"issue":"19","key":"11136_CR25","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1182\/blood.2020005517","volume":"137","author":"A Nakamura-Ishizu","year":"2021","unstructured":"Nakamura-Ishizu, A., Chin, D. W. L., Matsumura, T., et al. (2021). Prolonged maintenance of hematopoietic stem cells that escape from thrombopoietin deprivation. Blood, 137(19), 2609\u20132620.","journal-title":"Blood"},{"issue":"6","key":"11136_CR26","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.stem.2007.10.020","volume":"1","author":"H Yoshihara","year":"2007","unstructured":"Yoshihara, H., Arai, F., Hosokawa, K., et al. (2007). Thrombopoietin\/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell, 1(6), 685\u2013697.","journal-title":"Cell Stem Cell"},{"issue":"14","key":"11136_CR27","doi-asserted-by":"crossref","first-page":"8126","DOI":"10.1073\/pnas.96.14.8126","volume":"96","author":"M Yagi","year":"1999","unstructured":"Yagi, M., Ritchie, K. A., Sitnicka, E., et al. (1999). Sustained ex vivo expansion of hematopoietic stem cells mediated by thrombopoietin. Proceedings of the National Academy of Sciences of the United States of America, 96(14), 8126\u20138131.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"11136_CR28","doi-asserted-by":"crossref","unstructured":"Tajer, P., Cante-Barrett, K., Naber, B. A. E. (2022). IL3 Has a Detrimental Effect on Hematopoietic Stem Cell Self-Renewal in Transplantation Settings. International Journal of Molecular Sciences, 23(21).","DOI":"10.3390\/ijms232112736"},{"issue":"6","key":"11136_CR29","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3109\/21691401.2014.897630","volume":"43","author":"Z Du","year":"2015","unstructured":"Du, Z., Jin, H., Cai, H., et al. (2015). Hematopoietic repopulating ability of CD34+ progenitor cells ex vivo expanded with different cytokine combinations. Artificial Cells Nanomedicine and Biotechnology, 43(6), 398\u2013402.","journal-title":"Artificial Cells Nanomedicine and Biotechnology"},{"issue":"1","key":"11136_CR30","first-page":"92","volume":"1","author":"S Zhang","year":"2019","unstructured":"Zhang, S., Morita, M., Wang, Z., et al. (2019). Interleukin-12 supports in vitro self-renewal of long-term hematopoietic stem cells. Blood science (Baltimore Md), 1(1), 92\u2013101.","journal-title":"Blood science (Baltimore Md)"},{"issue":"11","key":"11136_CR31","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.exphem.2009.09.001","volume":"37","author":"T Nishino","year":"2009","unstructured":"Nishino, T., Miyaji, K., Ishiwata, N., et al. (2009). Ex vivo expansion of human hematopoietic stem cells by a small-molecule agonist of c-MPL. Experimental Hematology, 37(11), 1364\u20131377.","journal-title":"Experimental Hematology"},{"issue":"1","key":"11136_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/stem.160001","volume":"16","author":"MM Murone","year":"1998","unstructured":"Murone, M. M., Carpenter, D. A., & de Sauvage, F. J. (1998). Hematopoietic deficiencies in c-mpl and TPO knockout mice. Stem Cells, 16(1), 1\u20136.","journal-title":"Stem Cells"},{"issue":"7","key":"11136_CR33","first-page":"1883","volume":"106","author":"A O\u2019Neill","year":"2021","unstructured":"O\u2019Neill, A., Chin, D., Tan, D., et al. (2021). Thrombopoietin maintains cell numbers of hematopoietic stem and progenitor cells with megakaryopoietic potential. Haematologica, 106(7), 1883\u20131891.","journal-title":"Haematologica"},{"issue":"6","key":"11136_CR34","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1134\/S0026893319060025","volume":"53","author":"AV Belyaysky","year":"2019","unstructured":"Belyaysky, A. V. (2019). Niches of Hematopoietic Stem Cells in Bone Marrow. Molecular Biology, 53(6), 889\u2013895.","journal-title":"Molecular Biology"},{"issue":"9","key":"11136_CR35","first-page":"50","volume":"34","author":"G de Haan","year":"2006","unstructured":"de Haan, G., Gerritss, A., Bystrykh, L. V., et al. (2006). The polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Experimental Hematology, 34(9), 50\u201350.","journal-title":"Experimental Hematology"},{"issue":"3","key":"11136_CR36","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.18632\/oncotarget.6198","volume":"7","author":"L Herviou","year":"2016","unstructured":"Herviou, L., Cavalli, G., Cartron, G., et al. (2016). EZH2 in normal hematopoiesis and hematological malignancies. Oncotarget, 7(3), 2284\u20132296.","journal-title":"Oncotarget"},{"issue":"3","key":"11136_CR37","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.stem.2011.06.014","volume":"9","author":"A Matsumoto","year":"2011","unstructured":"Matsumoto, A., Takeishi, S., Kanie, T., et al. (2011). p57 Is Required for Quiescence and Maintenance of Adult Hematopoietic Stem Cells. Cell Stem Cell, 9(3), 262\u2013271.","journal-title":"Cell Stem Cell"},{"issue":"6","key":"11136_CR38","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.stem.2007.10.008","volume":"1","author":"H Qian","year":"2007","unstructured":"Qian, H., Buza-Vidas, N., Hyland, C. D., et al. (2007). Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell, 1(6), 671\u2013684.","journal-title":"Cell Stem Cell"},{"issue":"7","key":"11136_CR39","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.celrep.2018.10.059","volume":"25","author":"A Nakamura-Ishizu","year":"2018","unstructured":"Nakamura-Ishizu, A., Matsumura, T., Stumpf, P. S., et al. (2018). Thrombopoietin Metabolically Primes Hematopoietic Stem Cells to Megakaryocyte-Lineage Differentiation. Cell Reports, 25(7), 1772\u2013.","journal-title":"Cell Reports"},{"issue":"2","key":"11136_CR40","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/bloodadvances.2024014046","volume":"9","author":"MJ Williams","year":"2025","unstructured":"Williams, M. J., Wang, X., Bastos, H. P., et al. (2025). Maintenance of hematopoietic stem cells by tyrosine-unphosphorylated STAT5 and JAK inhibition. Blood Advances, 9(2), 291\u2013309.","journal-title":"Blood Advances"},{"issue":"2","key":"11136_CR41","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.stemcr.2023.12.004","volume":"19","author":"S Lee","year":"2024","unstructured":"Lee, S., & Zhan, H. (2024). Deciphering the differential impact of thrombopoietin\/MPL signaling on hematopoietic stem\/progenitor cell function in bone marrow and spleen. Stem Cell Reports, 19(2), 211\u2013223.","journal-title":"Stem Cell Reports"},{"issue":"20","key":"11136_CR42","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1182\/blood-2008-09-181107","volume":"113","author":"ZQ Wang","year":"2009","unstructured":"Wang, Z. Q., Li, G. Q., Tse, W., et al. (2009). Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacement. Blood, 113(20), 4856\u20134865.","journal-title":"Blood"},{"issue":"7470","key":"11136_CR43","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nature12495","volume":"502","author":"A Sanjuan-Pla","year":"2013","unstructured":"Sanjuan-Pla, A., Macaulay, I. C., Jensen, C. T., et al. (2013). Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy. Nature, 502(7470), 232\u2013.","journal-title":"Nature"},{"issue":"11","key":"11136_CR44","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/nm.3706","volume":"20","author":"M Zhao","year":"2014","unstructured":"Zhao, M., Perry, J. M., Marshall, H., et al. (2014). Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells. Nature Medicine, 20(11), 1321\u20131326.","journal-title":"Nature Medicine"},{"issue":"7440","key":"11136_CR45","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nature11926","volume":"495","author":"A Greenbaum","year":"2013","unstructured":"Greenbaum, A., Hsu, Y. M. S., Day, R. B., et al. (2013). CXCL12 in early mesenchymal progenitors is. required for haematopoietic stem-cell maintenance. Nature, 495(7440), 227\u2013230.","journal-title":"Nature"},{"key":"11136_CR46","doi-asserted-by":"crossref","unstructured":"Tian, Y. C., Zong, Y., Pang, Y. D. (2025). Platelets and diseases: signal transduction and advances in targeted therapy. Signal Transduction and Targeted Therapy, 10(1).","DOI":"10.1038\/s41392-025-02198-8"},{"issue":"10","key":"11136_CR47","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1182\/blood.2024025406","volume":"145","author":"M Kauppi","year":"2025","unstructured":"Kauppi, M., Hyland, C. D., Viney, E. M., et al. (2025). Cullin-5 controls the number of megakaryocytecommitted stem cells to prevent thrombocytosis in mice. Blood, 145(10), 1034\u20131046.","journal-title":"Blood"},{"issue":"3","key":"11136_CR48","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.molcel.2020.04.008","volume":"78","author":"B Psaila","year":"2020","unstructured":"Psaila, B., Wang, G. L., Rodriguez-Meira, A., et al. (2020). Single-Cell Analyses Reveal Megakaryocyte-Biased Hematopoiesis in Myelofibrosis and Identify Mutant Clone-Specific Targets. Molecular Cell, 78(3), 477\u2013.","journal-title":"Molecular Cell"},{"key":"11136_CR49","doi-asserted-by":"crossref","unstructured":"Manso, B. A., Baena, A., & Forsberg, E. C. (2024). From Hematopoietic Stem Cells to Platelets: Unifying Differentiation Pathways Identified by Lineage Tracing Mouse Models. Cells, 13(8).","DOI":"10.3390\/cells13080704"},{"issue":"14","key":"11136_CR50","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/blood-2017-08-743229","volume":"131","author":"ME Quach","year":"2018","unstructured":"Quach, M. E., Chen, W., & Li, R. (2018). Mechanisms of platelet clearance and translation to improve platelet storage. Blood, 131(14), 1512\u20131521.","journal-title":"Blood"},{"issue":"10","key":"11136_CR51","first-page":"A390","volume":"84","author":"FJ Desauvage","year":"1994","unstructured":"Desauvage, F. J., Gurney, A., Carvermoore, K., et al. (1994). THROMBOCYTOPENIA IN C-MPL DEFICIENT MICE. Blood, 84(10), A390\u2013A390.","journal-title":"Blood"},{"issue":"1","key":"11136_CR52","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.revmed.2020.05.017","volume":"42","author":"M Ebbo","year":"2021","unstructured":"Ebbo, M., Riviere, E., & Godeau, B. (2021). Adult immune thrombocytopenia and thrombopoietin receptor agonist: Ten years later. Revue De Medecine Interne, 42(1), 38\u201345.","journal-title":"Revue De Medecine Interne"},{"issue":"6","key":"11136_CR53","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","volume":"104","author":"W Ghanima","year":"2019","unstructured":"Ghanima, W., Cooper, N., Rodeghiero, F., et al. (2019). Thrombopoietin receptor agonists: ten years later. Haematologica, 104(6), 1112\u20131123.","journal-title":"Haematologica"},{"key":"11136_CR54","doi-asserted-by":"crossref","unstructured":"Li, L., Ni, R., Li, Z. (2022). Insights into Regulatory Factors in Megakaryocyte Development and Function: Basic Mechanisms and Potential Targets. Frontiers in Bioscience-Landmark, 27(11).","DOI":"10.31083\/j.fbl2711313"},{"key":"11136_CR55","doi-asserted-by":"crossref","unstructured":"Eaton, N., Boyd, E. K., Biswas, R. (2022). Endocytosis of the thrombopoietin receptor Mpl regulates megakaryocyte and erythroid maturation in mice. Frontiers in Oncology, 12.","DOI":"10.3389\/fonc.2022.959806"},{"issue":"3","key":"11136_CR56","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1182\/blood-2008-06-165985","volume":"116","author":"M Girardot","year":"2010","unstructured":"Girardot, M., Pecquet, C., Boukour, S., et al. (2010). miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets. Blood, 116(3), 437\u2013445.","journal-title":"Blood"},{"issue":"6","key":"11136_CR57","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1182\/blood-2014-08-593392","volume":"125","author":"N Xiao","year":"2015","unstructured":"Xiao, N., Laha, S., Das, S. P., et al. (2015). Ott1 (Rbm15) regulates thrombopoietin response in hematopoietic stem cells through alternative splicing of c-Mpl. Blood, 125(6), 941\u2013948.","journal-title":"Blood"},{"key":"11136_CR58","doi-asserted-by":"crossref","unstructured":"Gao, G., Moreira, J. D., Das, P. (2025). Histone lysine methyltransferases MLL3 and MLL4 direct gene expression to produce platelets efficiently. Nature Communications, 16(1).","DOI":"10.1038\/s41467-025-61247-6"},{"key":"11136_CR59","unstructured":"Pariser, D. N. (2021). Lung Megakaryocytes are a Novel Immune Modulatory Cell and Present Antigen to CD4\u2009+\u2009T Cells."},{"key":"11136_CR60","doi-asserted-by":"crossref","unstructured":"Kim, S., & Lee, K. W. (2025). Emerging Roles of Megakaryocytes in Immune Regulation and Potential Therapeutic Prospects. Cells, 14(21).","DOI":"10.3390\/cells14211677"},{"key":"11136_CR61","doi-asserted-by":"crossref","first-page":"100097","DOI":"10.1016\/j.pscia.2025.100097","volume":"3","author":"MS Ashaq","year":"2025","unstructured":"Ashaq, M. S., Wang, S., Guo, M., et al. (2025). Comprehensive multi-omics analysis of CD36 in pan-cancers: Evaluating role in prognosis, immune microenvironment, and therapeutic response. Pharm Sci Adv, 3, 100097.","journal-title":"Pharm Sci Adv"},{"key":"11136_CR62","doi-asserted-by":"crossref","unstructured":"Zhan, H., & Kaushansky, K. (2022). Megakaryocytes as the Regulator of the Hematopoietic Vascular Niche. Frontiers in Oncology, 12.","DOI":"10.3389\/fonc.2022.912060"},{"key":"11136_CR63","doi-asserted-by":"crossref","unstructured":"Roweth, H. G., Malloy, M. W., Goreczny, G. J. (2022). Pro-inflammatory megakaryocyte gene expression in murine models of breast cancer. Science Advances, 8(41).","DOI":"10.1126\/sciadv.abo5224"},{"key":"11136_CR64","doi-asserted-by":"crossref","unstructured":"Singh, S. V., Lucerne, A., & Ravid, K. (2025). Immune and Inflammatory Properties of Megakaryocytes. Cells, 14(14).","DOI":"10.3390\/cells14141053"},{"issue":"3","key":"11136_CR65","first-page":"343","volume":"46","author":"RSY Wong","year":"2024","unstructured":"Wong, R. S. Y., & Cheong, S. K. (2024). Beyond platelet production: Megakaryocytes\u2019 emerging roles in immunity and infection. Malaysian Journal of Pathology, 46(3), 343\u2013354.","journal-title":"Malaysian Journal of Pathology"},{"issue":"9","key":"11136_CR66","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S0301-472X(99)00069-7","volume":"27","author":"XQ Yan","year":"1999","unstructured":"Yan, X. Q., Lacey, D. L., Saris, C., et al. (1999). Ectopic overexpression of c-mpl by retroviral-mediated gene transfer suppressed megakaryopoiesis but enhanced erythropoiesis in mice. Experimental Hematology, 27(9), 1409\u20131417.","journal-title":"Experimental Hematology"},{"issue":"6","key":"11136_CR67","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/blood-2014-02-555318","volume":"125","author":"E Belay","year":"2015","unstructured":"Belay, E., Miller, C. P., Kortum, A. N., et al. (2015). A hyperactive Mpl-based cell growth switch drives macrophage-associated erythropoiesis through an erythroid-megakaryocytic precursor. Blood, 125(6), 1025\u20131033.","journal-title":"Blood"},{"issue":"6","key":"11136_CR68","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/stem.1677","volume":"32","author":"WS Kim","year":"2014","unstructured":"Kim, W. S., Zhu, Y., Deng, Q., et al. (2014). Erythropoiesis from Human Embryonic Stem Cells Through Erythropoietin-Independent AKT Signaling. Stem Cells, 32(6), 1503\u20131514.","journal-title":"Stem Cells"},{"issue":"2","key":"11136_CR69","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1365-2141.2010.08083.x","volume":"149","author":"EM Boyd","year":"2010","unstructured":"Boyd, E. M., Bench, A. J., Goday-Fernandez, A., et al. (2010). Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. British Journal of Haematology, 149(2), 250\u2013257.","journal-title":"British Journal of Haematology"},{"issue":"1","key":"11136_CR70","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","volume":"112","author":"PA Beer","year":"2008","unstructured":"Beer, P. A., Campbell, P. J., Scott, L. M., et al. (2008). MPL mutations in myeloproliferative disorders:: analysis of the PT-1 cohort. Blood, 112(1), 141\u2013149.","journal-title":"Blood"},{"issue":"10","key":"11136_CR71","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2007-05-089003","volume":"110","author":"R Chaligne","year":"2007","unstructured":"Chaligne, R., James, C., Tonetti, C., et al. (2007). Evidence for MPL W515L\/K mutations in hematopoietic stem cells in primitive myelofibrosis. Blood, 110(10), 3735\u20133743.","journal-title":"Blood"},{"key":"11136_CR72","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/jcla.24992","volume":"37","author":"EW Miller","year":"2023","unstructured":"Miller, E. W., Lamberson, C. M., Akabari, R. R., et al. (2023). Expanded molecular detection of MPL codon p.W515 and p.S505N mutations in myeloproliferative neoplasms. Journal of Clinical Laboratory Analysis, 37, 23\u201324.","journal-title":"Journal of Clinical Laboratory Analysis"},{"key":"11136_CR73","doi-asserted-by":"crossref","unstructured":"Morrell, R., Langabeer, S. E., Smyth, L. (2013). Nonfamilial, MPL S505N-Mutated Essential Thrombocythaemia. Case reports in hematology, 2013 729327\u2013729327.","DOI":"10.1155\/2013\/729327"},{"key":"11136_CR74","doi-asserted-by":"crossref","unstructured":"Alimam, S., Villiers, W., Dillon, R. (2019). Molecular, Epigenetic and Gene Expression Profiling of Triple Negative Essential Thrombocythaemia. Blood, 134.","DOI":"10.1182\/blood-2019-126008"},{"issue":"3","key":"11136_CR75","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood-2015-07-661983","volume":"127","author":"X Cabagnols","year":"2016","unstructured":"Cabagnols, X., Favale, F., Pasquier, F., et al. (2016). Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood, 127(3), 333\u2013342.","journal-title":"Blood"},{"issue":"6","key":"11136_CR76","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.exphem.2014.02.007","volume":"42","author":"V Sangkhae","year":"2014","unstructured":"Sangkhae, V., Saur, S. J., Kaushansky, A., et al. (2014). Phosphorylated c-Mpl tyrosine 591 regulates thrombopoietin-induced signaling. Experimental Hematology, 42(6), 477\u2013486.","journal-title":"Experimental Hematology"},{"issue":"10","key":"11136_CR77","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","volume":"123","author":"E Rumi","year":"2014","unstructured":"Rumi, E., Pietra, D., Ferretti, V., et al. (2014). JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood, 123(10), 1544\u20131551.","journal-title":"Blood"},{"issue":"11","key":"11136_CR78","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1007\/s00277-021-04617-6","volume":"100","author":"E Yang","year":"2021","unstructured":"Yang, E., Wang, M., Wang, Z., et al. (2021). Comparison of the effects between MPL and JAK2V617F on thrombosis and peripheral blood cell counts in patients with essential thrombocythemia: a meta-analysis. Annals of Hematology, 100(11), 2699\u20132706.","journal-title":"Annals of Hematology"},{"key":"11136_CR79","doi-asserted-by":"crossref","unstructured":"Asp, J., Andreasson, B., Hansson, U. (2016). Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome. Haematologica, 101(4).","DOI":"10.3324\/haematol.2015.138958"},{"issue":"12","key":"11136_CR80","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.3324\/haematol.2010.029306","volume":"95","author":"PA Beer","year":"2010","unstructured":"Beer, P. A., Ortmann, C. A., Stegelmann, F., et al. (2010). Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms. Haematologica-the Hematology Journal, 95(12), 2153\u20132156.","journal-title":"Haematologica-the Hematology Journal"},{"issue":"7","key":"11136_CR81","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman, Y., Lee, B. H., Mercher, T., et al. (2006). MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia. Plos Medicine, 3(7), 1140\u20131151.","journal-title":"Plos Medicine"},{"issue":"2","key":"11136_CR82","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s12185-021-03239-y","volume":"115","author":"N Saito","year":"2022","unstructured":"Saito, N., Yamauchi, T., Kawano, N., et al. (2022). Circulating CD34+cells of primary myelofibrosis patients contribute to myeloid-dominant hematopoiesis and bone marrow fibrosis in immunodeficient mice. International Journal of Hematology, 115(2), 198\u2013207.","journal-title":"International Journal of Hematology"},{"issue":"C","key":"11136_CR83","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.mce.2017.01.050","volume":"451","author":"JM O\u2019Sullivan","year":"2017","unstructured":"O\u2019Sullivan, J. M., & Harrison, C. N. (2017). JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms. Molecular and Cellular Endocrinology, 451(C), 71\u201379.","journal-title":"Molecular and Cellular Endocrinology"},{"key":"11136_CR84","doi-asserted-by":"crossref","unstructured":"Morsia, E., Torre, E., Poloni, A. (2022). Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications. International Journal of Molecular Sciences, 23(9).","DOI":"10.3390\/ijms23094573"},{"key":"11136_CR85","doi-asserted-by":"crossref","unstructured":"Yun, J., Kim, J. A., Hwang, B. (2018). Triple-Negative Myeloproliferative Neoplasms Vs. Calr, JAK2 or MPL-Mutated Myeloproliferative Neoplasms: Distinct Molecular Characteristics. Blood, 132.","DOI":"10.1182\/blood-2018-99-118013"},{"issue":"6","key":"11136_CR86","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","volume":"129","author":"E Rumi","year":"2017","unstructured":"Rumi, E., & Cazzola, M. (2017). Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood, 129(6), 680\u2013692.","journal-title":"Blood"},{"issue":"9","key":"11136_CR87","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/blood-2007-05-089326","volume":"110","author":"S Gery","year":"2007","unstructured":"Gery, S., Gueller, S., Chumakova, K., et al. (2007). Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders. Blood, 110(9), 3360\u20133364.","journal-title":"Blood"},{"key":"11136_CR88","doi-asserted-by":"crossref","unstructured":"Bader, M. S., & Meyer, S. C. (2022). JAK2 in Myeloproliferative Neoplasms: Still a Protagonist. Pharmaceuticals, 15(2).","DOI":"10.3390\/ph15020160"},{"key":"11136_CR89","doi-asserted-by":"crossref","unstructured":"Tiryaki, T. O., Aday, A. D., Nalcaci, M. (2025). CalR and MPL Driver Mutations and Their Role in the Diagnosis and Clinical Course of JAK2-Unmutated Chronic Myeloproliferative Neoplasm: Results from a Pilot Single-Center Study. Medicina-Lithuania, 61(6).","DOI":"10.3390\/medicina61060962"},{"key":"11136_CR90","doi-asserted-by":"crossref","unstructured":"Plo, I., Bellann\u00e9-Chantelot, C., Mosca, M. (2017). Genetic Alterations of the Thrombopoietin\/MPL\/JAK2 Axis Impacting Megakaryopoiesis. Frontiers in Endocrinology, 8.","DOI":"10.3389\/fendo.2017.00234"},{"key":"11136_CR91","doi-asserted-by":"crossref","unstructured":"Craver, B. M., Thanh Kim, N., Nguyen, J. (2020). The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells. Experimental Hematology & Oncology, 9(1).","DOI":"10.1186\/s40164-019-0157-6"},{"issue":"9","key":"11136_CR92","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1182\/bloodadvances.2023010950","volume":"8","author":"M Usart","year":"2024","unstructured":"Usart, M., Hansen, N., Stetka, J., et al. (2024). The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN. Blood Advances, 8(9), 2312\u20132325.","journal-title":"Blood Advances"},{"key":"11136_CR93","doi-asserted-by":"crossref","unstructured":"Coen, C., Yan, J., Saygin, C. (2023). Glutamine Metabolism Is Altered in Myeloproliferative Neoplasms and Represents a Potential Novel Therapeutic Target. Blood, 142.","DOI":"10.1182\/blood-2023-189731"},{"key":"11136_CR94","doi-asserted-by":"crossref","unstructured":"Zhan, H., Girnun, G., Dong, K. (2014). Targeting Glutamine Metabolism in Myeloproliferative Neoplasms. Blood, 124(21).","DOI":"10.1182\/blood.V124.21.1869.1869"},{"key":"11136_CR95","doi-asserted-by":"crossref","unstructured":"Hajmirza, A., Emadali, A., Gauthier, A. (2018). BET Family Protein BRD4: An Emerging Actor in NF\u03baB Signaling in Inflammation and Cancer. Biomedicines, 6(1).","DOI":"10.3390\/biomedicines6010016"},{"key":"11136_CR96","doi-asserted-by":"crossref","unstructured":"Pusey, M., Trivedi, G., Collins, B. (2023). Preclinical characterization of the BET inhibitor, INCB057643, in combination with ruxolitinib for treatment of myeloproliferative neoplasms (MPN). Cancer Research, 83(7).","DOI":"10.1158\/1538-7445.AM2023-6274"},{"key":"11136_CR97","doi-asserted-by":"crossref","unstructured":"Yao, J. C., Oetjen, K. A., Wang, T. (2022). TGF-\u03b2 signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche. Journal of Clinical Investigation, 132(11).","DOI":"10.1172\/JCI154092"},{"issue":"26","key":"11136_CR98","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1182\/blood.2022018859","volume":"140","author":"JS Jutzi","year":"2022","unstructured":"Jutzi, J. S., & Mullally, A. (2022). Two to tango! IL-13 and TGF-\u03b2 drive myelofibrosis. Blood, 140(26), 2767\u20132768.","journal-title":"Blood"},{"issue":"12","key":"11136_CR99","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/nm.3995","volume":"21","author":"QJ Wen","year":"2015","unstructured":"Wen, Q. J., Yang, Q., Goldenson, B., et al. (2015). Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nature Medicine, 21(12), 1473\u2013.","journal-title":"Nature Medicine"},{"key":"11136_CR100","doi-asserted-by":"crossref","unstructured":"Rai, S., Grockowiak, E., Hansen, N. (2022). Inhibition of interleukin-1\u03b2 reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm. Nature Communications, 13(1).","DOI":"10.1038\/s41467-022-32927-4"},{"issue":"3","key":"11136_CR101","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/jcb.10141","volume":"85","author":"Y Zhang","year":"2002","unstructured":"Zhang, Y., Sun, S. S., Wang, Z. Y., et al. (2002). Signaling by the Mpl receptor involves IKK and NF-\u03baB. Journal of Cellular Biochemistry, 85(3), 523\u2013535.","journal-title":"Journal of Cellular Biochemistry"},{"issue":"26","key":"11136_CR102","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1182\/blood.2022017326","volume":"140","author":"J Melo-Cardenas","year":"2022","unstructured":"Melo-Cardenas, J., Bezavada, L., Crawford, J. C., et al. (2022). IL-13\/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms. Blood, 140(26), 2805\u20132817.","journal-title":"Blood"},{"key":"11136_CR103","doi-asserted-by":"crossref","unstructured":"Gotfredsen, K., Liisborg, C., Skov, V. (2023). Serum levels of IL-4, IL-13 and IL-33 in patients with age-related macular degeneration and myeloproliferative neoplasms. Scientific Reports, 13(1).","DOI":"10.1038\/s41598-023-31078-w"},{"issue":"6","key":"11136_CR104","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","volume":"129","author":"W Vainchenker","year":"2017","unstructured":"Vainchenker, W., & Kralovics, R. (2017). Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood, 129(6), 667\u2013679.","journal-title":"Blood"},{"key":"11136_CR105","doi-asserted-by":"crossref","unstructured":"Loscocco, G. G., Gesullo, F., Capecchi, G. (2024). One thousand patients with essential thrombocythemia: the Florence-CRIMM experience. Blood Cancer Journal, 14(1).","DOI":"10.1038\/s41408-023-00968-7"},{"issue":"2","key":"11136_CR106","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","volume":"30","author":"D Pietra","year":"2016","unstructured":"Pietra, D., Rumi, E., Ferretti, V. V., et al. (2016). Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia, 30(2), 431\u2013438.","journal-title":"Leukemia"},{"key":"11136_CR107","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.V128.22.22.22","volume":"128","author":"BM Getta","year":"2016","unstructured":"Getta, B. M., Zabor, E. C., Devlin, S., et al. (2016). RAS Pathway Mutations Are Associated with Proliferative Features and Frequently Co-Occur with TET2 mutationsin Philadelphia Negative MPN Subtypes. Blood, 128, 22.","journal-title":"Blood"},{"issue":"5","key":"11136_CR108","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1159\/000512929","volume":"144","author":"OA Shahin","year":"2021","unstructured":"Shahin, O. A., Chifotides, H. T., Bose, P., et al. (2021). Accelerated Phase of Myeloproliferative Neoplasms. Acta Haematologica, 144(5), 484\u2013499.","journal-title":"Acta Haematologica"},{"key":"11136_CR109","doi-asserted-by":"crossref","unstructured":"Sharma, M., Bhavani, C., Suresh, S. B. (2021). Gene expression profiling of CD34(+) cells from patients with myeloproliferative neoplasms. Oncology Letters, 21(3).","DOI":"10.3892\/ol.2021.12465"},{"key":"11136_CR110","doi-asserted-by":"crossref","unstructured":"Kao, H. W., Chang, H., Kuo, M. C. (2025). Genetic evolution of myeloproliferative neoplasms from chronic phase to blastic phase: An analysis of 46 paired samples. Cancer, 131(16).","DOI":"10.1002\/cncr.70048"},{"key":"11136_CR111","doi-asserted-by":"crossref","unstructured":"Yang, Y. T., Cathelin, S., Liu, A. C. H. (2025). TET2 deficiency increases the competitive advantage of hematopoietic stem and progenitor cells through upregulation of thrombopoietin receptor signaling. Nature Communications, 16(1).","DOI":"10.1038\/s41467-025-57614-y"},{"issue":"9","key":"11136_CR112","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1158\/1078-0432.CCR-23-0372","volume":"30","author":"M Kandarpa","year":"2024","unstructured":"Kandarpa, M., Robinson, D., Wu, Y. M., et al. (2024). Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations. Clinical Cancer Research, 30(9), 1972\u20131983.","journal-title":"Clinical Cancer Research"},{"key":"11136_CR113","first-page":"19","volume":"17","author":"XY Ma","year":"2025","unstructured":"Ma, X. Y., Zhou, Z. B., Gu, S. Y., et al. (2025). Advances in the Diagnosis and Treatment of Myeloproliferative Neoplasms (MPNs). Cancers, 17, 19.","journal-title":"Cancers"},{"key":"11136_CR114","doi-asserted-by":"crossref","first-page":"100052","DOI":"10.1016\/j.pscia.2024.100052","volume":"2","author":"MS Ashaq","year":"2024","unstructured":"Ashaq, M. S., Zhou, Q., Li, Z., et al. (2024). Novel targeted therapies in chronic myeloid leukemia. Pharm Sci Adv, 2, 100052.","journal-title":"Pharm Sci Adv"},{"issue":"5","key":"11136_CR115","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s12185-022-03335-7","volume":"115","author":"GG Loscocco","year":"2022","unstructured":"Loscocco, G. G., & Vannucchi, A. M. (2022). Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives. International Journal of Hematology, 115(5), 626\u2013644.","journal-title":"International Journal of Hematology"},{"key":"11136_CR116","doi-asserted-by":"crossref","unstructured":"Mesa, R. A., & Cortes, J. (2013). Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. Journal of Hematology & Oncology, 6.","DOI":"10.1186\/1756-8722-6-79"},{"key":"11136_CR117","doi-asserted-by":"crossref","unstructured":"Lim, K. H., Chang, Y. C., Chiang, Y. H. (2019). Acquired Resistance to JAK Inhibitors in Calr-Mutated Myeloproliferative Neoplasms. Blood, 134.","DOI":"10.1182\/blood-2019-124420"},{"issue":"8","key":"11136_CR118","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1007\/s00277-024-05867-w","volume":"103","author":"S Isfort","year":"2024","unstructured":"Isfort, S., von Bubnoff, N., Al-Ali, H. K., et al. (2024). FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN). Annals of Hematology, 103(8), 2775\u20132785.","journal-title":"Annals of Hematology"},{"issue":"6","key":"11136_CR119","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1074\/jbc.M115.696534","volume":"291","author":"E Leroy","year":"2016","unstructured":"Leroy, E., Defour, J. P., Sato, T., et al. (2016). His499 Regulates Dimerization and Prevents Oncogenic Activation by Asparagine Mutations of the Human Thrombopoietin Receptor. Journal of Biological Chemistry, 291(6), 2974\u20132987.","journal-title":"Journal of Biological Chemistry"},{"issue":"12","key":"11136_CR120","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood.2019003240","volume":"135","author":"G Levy","year":"2020","unstructured":"Levy, G., Carillo, S., Papoular, B., et al. (2020). MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491. Blood, 135(12), 948\u2013953.","journal-title":"Blood"},{"issue":"19","key":"11136_CR121","doi-asserted-by":"crossref","first-page":"9073","DOI":"10.1111\/jcmm.16878","volume":"25","author":"A Roy","year":"2021","unstructured":"Roy, A., Shrivastva, S., & Naseer, S. (2021). In and out: Traffic and dynamics of thrombopoietin receptor. Journal of Cellular and Molecular Medicine, 25(19), 9073\u20139083.","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"11136_CR122","doi-asserted-by":"crossref","unstructured":"Shin, J., Kim, M. J., Quan, X. (2023). Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia. Bmc Cancer, 23(1).","DOI":"10.1186\/s12885-023-10975-3"},{"key":"11136_CR123","doi-asserted-by":"crossref","unstructured":"Abbasi, A. M., Shaikh, M. U., Ali, N. (2022). Response of Eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience. Leukemia Research Reports, 17.","DOI":"10.1016\/j.lrr.2022.100295"},{"key":"11136_CR124","doi-asserted-by":"crossref","unstructured":"Lin, X. J., Yang, C., Liu, Z. W. (2025). Effective treatment of refractory aplastic anemia with romiplostim after failure of multiple thrombopoietin receptor agonists: a single-center retrospective study. Annals of Medicine, 57(1).","DOI":"10.1080\/07853890.2025.2514791"},{"issue":"32","key":"11136_CR125","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1200\/JCO.22.01972","volume":"41","author":"J Mascarenhas","year":"2023","unstructured":"Mascarenhas, J., Kremyanskaya, M., Patriarca, A., et al. (2023). MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naive Myelofibrosis. Journal of Clinical Oncology, 41(32), 4993\u2013.","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"11136_CR126","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/s41591-025-03572-3","volume":"31","author":"RK Rampal","year":"2025","unstructured":"Rampal, R. K., Grosicki, S., Chraniuk, D., et al. (2025). Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial. Nature Medicine, 31(5), 1531\u20131538.","journal-title":"Nature Medicine"},{"key":"11136_CR127","doi-asserted-by":"crossref","unstructured":"Gill, H. (2022). Lysine-Specific Demethylase 1 (LSD1\/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis. Cells, 11(13).","DOI":"10.3390\/cells11132107"},{"issue":"15","key":"11136_CR128","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1200\/JCO.21.02188","volume":"40","author":"CN Harrison","year":"2022","unstructured":"Harrison, C. N., Garcia, J. S., Somervaille, T. C. P., et al. (2022). Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. Journal of Clinical Oncology, 40(15), 1671\u2013.","journal-title":"Journal of Clinical Oncology"},{"issue":"18","key":"11136_CR129","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1158\/1078-0432.CCR-23-0276","volume":"29","author":"J Mascarenhas","year":"2023","unstructured":"Mascarenhas, J., Migliaccio, A. R., Kosiorek, H., et al. (2023). A Phase Ib Trial of AVID200, a TGF\u03b2 1\/3 Trap, in Patients with Myelofibrosis. Clinical Cancer Research, 29(18), 3622\u20133632.","journal-title":"Clinical Cancer Research"},{"key":"11136_CR130","doi-asserted-by":"crossref","unstructured":"Carturan, A., Mor\u00e8, S., Poloni, A. (2024). Shaping the Future of Myeloproliferative Neoplasm Therapy: Immune-Based Strategies and Targeted Innovations. Cancers, 16(23).","DOI":"10.3390\/cancers16234113"},{"key":"11136_CR131","doi-asserted-by":"crossref","unstructured":"Wang, J. C., & Sun, L. S. (2022). PD-1\/PD-L1, MDSC Pathways, and Checkpoint Inhibitor Therapy in Ph(-) Myeloproliferative Neoplasm: A Review. International Journal of Molecular Sciences, 23(10).","DOI":"10.3390\/ijms23105837"}],"container-title":["Stem Cell Reviews and Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-026-11136-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12015-026-11136-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-026-11136-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:31:51Z","timestamp":1780662711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12015-026-11136-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":131,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["11136"],"URL":"https:\/\/doi.org\/10.1007\/s12015-026-11136-2","relation":{},"ISSN":["2629-3269","2629-3277"],"issn-type":[{"value":"2629-3269","type":"print"},{"value":"2629-3277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All listed authors have approved the manuscript and agree with its submission for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}]}}